Insider · CIK 0001653052
Eric Crombez
Files at ABEO (ABEONA THERAPEUTICS INC.), RARE (Ultragenyx Pharmaceutical Inc.). First filing Mar 4, 2025, latest May 5, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RARE: Ultragenyx Pharmaceutical Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | RAREsell Ultragenyx Pharmaceutical Inc. | $29k 762 shares | -1% | +14% from low-40% from high | |
| 51Moderate | Ultragenyx Pharmaceutical Inc. | $377k 8,945 shares | -11% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | RARE Ultragenyx Pharmaceutical Inc. | SOpen-market sale Common Stock | -242 | $35.11 | $8,497 | 71,680 | May 5, 2025 |
| May 5, 2025 | RARE Ultragenyx Pharmaceutical Inc. | SOpen-market sale Common Stock | -520 | $39.24 | $20k | 71,530 | May 5, 2025 |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Common Stock | +16,813 | $0.00 | $0 | 65,244 | Mar 4, 2025 |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Common Stock | +14,971 | $0.00 | $0 | 80,215 | Mar 4, 2025 |
| Mar 3, 2025 | RARE Ultragenyx Pharmaceutical Inc. | SOpen-market sale Common Stock | -8,945 | $42.10 | $377k | 71,922 | Mar 4, 2025 |
| Mar 1, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Stock Ooption (Right to Buy)derivative | +30,246 | $0.00 | $0 | 30,246 | Mar 4, 2025 |
| Jan 31, 2025 | ABEO ABEONA THERAPEUTICS INC. | AGrant or award Common Stock | +36,101 | $0.00 | $0 | 47,145 | Feb 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.